ArticleCancer reports (Hoboken, N.J.)2026
Development of Glioblastoma Multiforme in Patients With Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma: A Case Series.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHuman papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV+ OPC) patients typically exhibit reduced rates of second primary malignancies (SPMs) compared to HPV-negative head and neck cancer patients. While HPV+ OPC patients may be predisposed to SPMs in HPV-associated anatomical sites, the metachronous presentation of an HPV+ OPC and subsequent glioblastoma multiforme (GBM) has not been previously documented. CASES: We present two cases of HPV+ OPC patients who developed GBMs within a short period after definitive therapy.
methodsComprehensive whole exome sequencing (WES) was performed on paired GBM, oropharyngeal, and matched normal tissues from two HPV+ OPC patients who developed GBMs within a short period after definitive therapy, with the goal of identifying shared somatic and germline variants. Bioinformatic analyses included variant calling, annotation, and pathway enrichment.
resultsWES revealed a shared CEP104 missense mutation among both oropharyngeal tumors as well as a potential KIR2DL4 germline variant in the second patient, suggesting a possible role for disrupted NK cell immunity in driving these cancers.
conclusionAlthough these cases were likely random events, they illustrate the diagnostic and therapeutic challenges of GBM following HPV+ OPC and underscore the importance of personalized genomic assessment in HPV+ OPC survivors, who may develop non-head and neck SPMs unrelated to field cancerization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.